Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Neuro-Oncology, Journal Year: 2020, Volume and Issue: 22(8), P. 1073 - 1113

Published: April 20, 2020

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause morbidity mortality. In recent years there have been advances in understanding molecular pathogenesis biology these tumors, but this has not translated into significantly improved outcomes for patients. consensus review from Society Neuro-Oncology (SNO) European Association (EANO), current management isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. addition, novel therapies such as targeted therapies, agents targeting DNA damage response metabolism, immunotherapies, viral reviewed, well challenges future directions research.

Language: Английский

---

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

Cell, Journal Year: 2020, Volume and Issue: 181(7), P. 1643 - 1660.e17

Published: May 28, 2020

Language: Английский

---

PROTACs: great opportunities for academia and industry

Signal Transduction and Targeted Therapy, Journal Year: 2019, Volume and Issue: 4(1)

Published: Dec. 24, 2019

Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem. Another disturbing statistic limited number drug targets, which presently only 20-25% all protein targets that currently being studied. Moreover, focus current explorations their enzymatic functions, ignores functions from scaffold moiety. As promising appealing technology, PROteolysis TArgeting Chimeras (PROTACs) have attracted great attention both academia industry for finding available approaches to solve above problems. PROTACs regulate function by degrading target proteins instead inhibiting them, providing more sensitivity drug-resistant greater chance affect nonenzymatic functions. been proven show better selectivity compared classic inhibitors. can be described as chemical knockdown approach with rapidity reversibility, presents new different biology other gene editing tools avoiding misinterpretations arise potential genetic compensation and/or spontaneous mutations. PRTOACs widely explored throughout world outperformed not cancer diseases, but also immune disorders, viral infections neurodegenerative diseases. present very powerful crossing hurdles discovery tool development biology, efforts needed gain get deeper insight into efficacy safety clinic. More binders E3 ligases applicable developing waiting exploration.

Language: Английский

---

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Pharmacological Research, Journal Year: 2021, Volume and Issue: 171, P. 105780 - 105780

Published: July 21, 2021

Language: Английский

---

Emerging therapies for glioblastoma: current state and future directions

Journal of Experimental & Clinical Cancer Research, Journal Year: 2022, Volume and Issue: 41(1)

Published: April 15, 2022

Abstract Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an extremely poor prognosis. Given survival currently approved treatments for GBM, new therapeutic strategies are urgently needed. Advances in decades of investment basic science glioblastoma rapidly translated into innovative clinical trials, utilizing improved genetic and epigenetic profiling as well microenvironment immune system interactions. Following these encouraging findings, immunotherapy including checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, vaccine therapy have offered hope improving GBM outcomes; ongoing studies using combinatorial therapies aim minimizing adverse side-effects augmenting antitumor responses. In addition, techniques to overcome blood-brain barrier (BBB) targeted delivery being tested trials patients recurrent GBM. Here, we set forth rationales promising treating review potential novel agents, current status preclinical discuss challenges future perspectives immuno-oncology.

Language: Английский

---

A review of glioblastoma immunotherapy

Journal of Neuro-Oncology, Journal Year: 2020, Volume and Issue: 151(1), P. 41 - 53

Published: April 6, 2020

Language: Английский

---

Advances in local therapy for glioblastoma — taking the fight to the tumour

Nature Reviews Neurology, Journal Year: 2022, Volume and Issue: 18(4), P. 221 - 236

Published: March 11, 2022

Language: Английский

---

Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment

Molecular Therapy, Journal Year: 2022, Volume and Issue: 30(10), P. 3133 - 3154

Published: April 9, 2022

Exosomes have a crucial role in intercellular communication and mediate interactions between tumor cells tumor-associated macrophages (TAMs). Exosome-encapsulated non-coding RNAs (ncRNAs) are involved various physiological processes. Tumor-derived exosomal ncRNAs induce M2 macrophage polarization through signaling pathway activation, signal transduction, transcriptional post-transcriptional regulation. Conversely, TAM-derived promote proliferation, metastasis, angiogenesis, chemoresistance, immunosuppression. MicroRNAs gene silencing by directly targeting mRNAs, whereas lncRNAs circRNAs act as miRNA sponges to indirectly regulate protein expressions. The of tumor-host is ubiquitous. Current research increasingly focused on the microenvironment. On basis "cancer-immunity cycle" hypothesis, we discuss effects immune T cell exhaustion, overexpression programmed death ligands, create immunosuppressive Furthermore, potential applications prospects clinical biomarkers drug delivery systems. Non-coding do not encode proteins but control expression function.1Hombach S. Kretz M. RNAs: classification, biology functioning.Adv. Exp. Med. Biol. 2016; 937: 3-17Crossref PubMed Scopus (346) Google Scholar, 2Chan J.J. Tay Y. Noncoding RNA:RNA regulatory networks cancer.Int. J. Mol. Sci. 2018; 19: 1310Crossref (608) 3Guil Esteller RNA-RNA regulation: coding noncoding players.Trends Biochem. 2015; 40: 248-256Abstract Full Text PDF Scholar Several types ncRNAs, including microRNAs (miRNAs), long (lncRNAs), circular (circRNAs), affect growth, metabolism multiple mechanisms.3Guil 4Anastasiadou E. Jacob L.S. Slack F.J. RNA cancer.Nat. Rev. Cancer. 18: 5-18Crossref (900) 5Goodall G.J. Wickramasinghe V.O. 2021; 21: 22-36Crossref (337) miRNAs 20–25 nucleotide that at level binding 3′ untranslated region (3′ UTR) target thus regulating other cellular processes.6Ha Kim V.N. Regulation microRNA biogenesis.Nat. Cell 2014; 15: 509-524Crossref (3372) Scholar,7Dong H. Lei Ding L. Wen Ju Zhang X. MicroRNA: function, detection, bioanalysis.Chem. 2013; 113: 6207-6233Crossref (823) longer than 200 nucleotides regulation nucleus cytoplasm.8Chen L.L. Linking localization function.Trends 41: 761-772Abstract (592) Scholar,9Quinn Chang H.Y. Unique features biogenesis function.Nat. Genet. 17: 47-62Crossref (2150) modulate stability, translation, translocation mRNAs.9Quinn Scholar,10Statello Guo C.J. Chen Huarte Gene its biological functions.Nat. 22: 96-118Crossref (817) increase mRNA expressions sponging competitive endogenous (ceRNAs), secreted either alone or bound proteins.11Tay Rinn Pandolfi P.P. multilayered complexity ceRNA crosstalk competition.Nature. 505: 344-352Crossref (2450) Scholar,12Lin C. Yang Long cancer: wiring circuitry.Trends 28: 287-301Abstract (330) characterized covalently closed-loop structure without 5′ cap poly(A) tail.13Yu C.Y. Kuo H.C. emerging roles functions their generation.J. Biomed. 2019; 26: 29Crossref (167) Scholar,14Kristensen Andersen M.S. Stagsted L.V.W. Ebbesen K.K. Hansen T.B. Kjems biogenesis, characterization RNAs.Nat. 20: 675-691Crossref (1539) These implicated spongings, interactions, nuclear transcription pre-mRNA splicing.15Wang R. Li N. Jia Pan Liang CircNT5E acts sponge miR-422a glioblastoma tumorigenesis.Cancer Res. 78: 4812-4825Crossref (199) Scholar,16Qian Yu Z. Meng Huang Wang P. significance human cancers.Biochim. Biophys. Acta 1870: 247-260Crossref (0) 40–150 nm extracellular vesicles pathological processes mediating communication.17Hessvik N.P. Llorente A. knowledge exosome release.Cell Life 75: 193-208Crossref (1112) Scholar,18Pegtel D.M. Gould S.J. Exosomes.Annu. 88: 487-514Crossref (793) content exosomes released donor protected from enzymatic hydrolysis.19Abels E.R. Breakefield X.O. Introduction vesicles: cargo selection, content, release, uptake.Cell. Neurobiol. 36: 301-312Crossref (713) 20Mathieu Martin-Jaular Lavieu G. Théry Specificities secretion uptake for cell-to-cell communication.Nat. 9-17Crossref (1420) 21Mashouri Yousefi Aref A.R. Ahadi A.M. Molaei F. Alahari S.K. Exosomes: composition, mechanisms cancer metastasis resistance.Mol. 75Crossref (410) fundamental resistance.21Mashouri 22van Niel D'Angelo Raposo Shedding light vesicles.Nat. 213-228Crossref (2898) 23Zhang D. development, immunity.Biochim. 1871: 455-468Crossref (215) Tumoral secrete microenvironment (TIME).23Zhang Scholar,24Kalluri function cancer.J. Clin. Invest. 126: 1208-1215Crossref (967) (TEXs) immunological activities, polarization, regulation, inhibition natural killer (NK) activity.25Whiteside T.L. progression.Adv. Chem. 74: 103-141Crossref (402) 26Kok V.C. C.C. Cancer-derived exosomes: biomarker development.Int. Nanomed. 2020; 8019-8036Crossref (50) 27Greening D.W. Gopal Xu Simpson R.J. W. cancer.Semin. Dev. 72-81Crossref (401) TEXs also malignancy, suggesting key tumoral cells.28Xie Zhou Fang Su Tu Extracellular immunotherapy.Adv. 6: 1901779Crossref (103) 29Veerman R.E. Güçlüler Akpinar Eldh Gabrielsson Immune cell-derived - therapeutic applications.Trends 25: 382-394Abstract (110) 30Yan Jiang cancer-immunity cycle.Trends 506-517Abstract (46) development immunosuppression attracted increasing attention.31Sun Shi K. Liu Q. Song Yuan Effect applications.Mol. 147Crossref 32Cheng Zhu Peng Exosomal Glioma: 66Crossref (131) 33Xie Dang Yue Zhai Yan Lu cancer.Mol. 37Crossref (134) can be used because high encapsulation efficiency ability transport anti-cancer drugs, agents, nucleic acids, gene-editing systems such CRISPR-Cas9.34Pullan J.E. Confeld M.I. Osborn J.K. Sarkar Mallik carriers therapy.Mol. Pharm. 16: 1789-1798Crossref (76) 35Liu Cheng Delivery strategies CRISPR-Cas9 system applications.J. Control. Release. 2017; 266: 17-26Crossref (257) 36Ghaemi Bagheri Abnous Taghdisi S.M. Ramezani Alibolandi CRISPR-cas9 genome editing targeted therapy.Life 267: 118969Crossref (7) Macrophages phagocytic cells, phenotypes influenced cytokines factors TIME.37Belgiovine D'Incalci Allavena Frapolli Tumor-associated anti-tumor therapies: complex links.Cell. 73: 2411-2424Crossref assume classically activated pro-inflammatory (M1) phenotype an alternatively anti-inflammatory (M2) phenotype.38Orecchioni Ghosheh Pramod A.B. Ley Macrophage polarization: different signatures M1(LPS+) vs. Classically M2(LPS-) Alternatively macrophages.Front. Immunol. 10: 1084Crossref (541) (TAMs) M1 early stages cancer.37Belgiovine In later stage, growth mediators, IL-4, IL-10, TGF-β, expressed TIME, inducing polarization.37Belgiovine M1-M2 highly dynamic reversible. TAMs produce inhibit activity TIME.39Yin Han Zheng B. Zhao SALL4-mediated upregulation miR-146a-5p drives T-cell exhaustion HCC.Oncoimmunology. 8: 1601479Crossref (3) TAM infiltration solid tumors underscores these progression immunosuppression.39Yin 40Ruffell Coussens L.M. resistance cancer.Cancer Cell. 27: 462-472Abstract (800) 41Sica Erreni Porta pathology.Cell. 72: 4111-4126Crossref (352) divided into M2a, M2b, M2c, M2d.42Rőszer T. Understanding mysterious activation markers effector mechanisms.Mediators Inflamm. 2015: 816460Crossref M2a subgroup IL-4 IL-13 produces CD163, CD206, IL1Ra.42Rőszer M2b stimulated complexes bacterial lipopolysaccharide CD86, IL-6, TNF-α.42Rőszer M2c induced glucocorticoids, TGF-β TGF-β; addition, this active against apoptotic cells.42Rőszer M2d subgroup, IL-6 adenosine, secretes (high levels IL-10 low IL-12) vascular endothelial factor (VEGF) angiogenesis.42Rőszer Some pathways switch.41Sica Scholar,43Shapouri-Moghaddam Mohammadian Vazini Taghadosi Esmaeili S.A. Mardani Seifi Mohammadi Afshari J.T. Sahebkar plasticity, health disease.J. Physiol. 233: 6425-6440Crossref (1441) Pro-inflammatory malignant behavior, promotes tumorigenesis evasion.41Sica Therefore, fine-tuned TIME. Tumor tissues may contain mixed populations with spectrum states. However, review, assumed phenotype, described literature.37Belgiovine Increased attention has been given TAMs. polarized support forming cycle which (Figure 1). This review discusses during initiation controlled influence formation TIME based model, application diagnostic prognostic targets. involves networks.38Orecchioni phosphatidylinositol 3-kinase (PI3K)/AKT JAK/STAT factors, transducer activator (STAT) family, peroxisome proliferator-activated receptor-γ (PPARγ), interferon polarization.44Czimmerer Daniel Horvath Rückerl Nagy Kiss Peloquin Budai M.M. Cuaranta-Monroy I. Simandi et al.The STAT6 mediates direct repression inflammatory enhancers limits macrophages.Immunity. 48: 75-90.e76Abstract (112) Scholar,45Vergadi Ieronymaki Lyroni Vaporidi Tsatsanis Akt M1/M2 polarization.J. 198: 1006-1014Crossref (398) Tumors controlling factors. For instance, HPV+ head neck squamous carcinoma (HNSCC), miR-9 was enriched transported macrophages, downregulating PPARδ.46Tong Mao Xie Sun Wei HPV + HNSCC-derived induces increases radiosensitivity.Cancer Lett. 478: 34-44Crossref (23) miR-451/miR-21 were detected primary multiforme (GBM) taken up brain mice, decreasing c-Myc levels. miR-21 miR-451 increased microglia co-cultured GBM heparin reduced effect.47van der Vos K.E. Abels Lai Carrizosa Oakley Prabhakar Mardini O. Crommentuijn M.H. Skog al.Directly visualized glioblastoma-derived transfer microglia/macrophages brain.Neuro Oncol. 58-69Crossref (207) prostate (PCa), let-7a-5p let7-b, -g, -i downregulated integrin-β3, causing PCa migration.48Ferguson Lee Deci Nguyen phenotypic distinct sources: comparative study composition.AAPS 67Crossref lncRNA TUC339 hepatocellular (HCC) promoted leading cytokine production, compromised phagocytosis, decreased co-stimulatory molecule macrophages.49Kogure I.K. Lin W.L. Patel vesicle-mediated novel TUC339: mechanism cancer.Genes 4: 261-272Crossref (239) Scholar,50Li Wu HCC-derived TUC339.Int. 2958Crossref (36) receptor CXCR chemokine pathways, explain underlying regulation.50Li miR-21-5p colorectal (CRC) cells.51Shao Shen al.Colorectal cancer-derived small establish premetastatic niche liver metastasis.Carcinogenesis. 39: 1368-1379Crossref (6) CRC lines SW480, SW620, LoVo injected nude mice significantly macrophages. via TLR7 pre-metastatic survival colonization, ultimately metastasis.51Shao metabolic enzymes. melanoma miR-125b-5p lysosomal acid lipase A switching survival.52Gerloff Lützkendorf Moritz R.K.C. Wersig Mäder Müller L.P. Sunderkötter Melanoma-derived educates associated (LIPA).Cancers. 12: 464Crossref BMP-7, PI3K/AKT pathway.45Vergadi Scholar,53Covarrubias A.J. Aksoylar H.I. Horng Control mTOR signaling.Semin. 286-296Crossref (189) Scholar,54Zhao Kong F.Q. Jie A.D. Y.Q. D.D. Z.Q. al.Macrophage MSR1 BMSC osteogenic differentiation M2-like activating PI3K/AKT/GSK3β/β-catenin pathway.Theranostics. 17-35Crossref (37) Phosphatase tension homolog deleted chromosome ten (PTEN) inhibits AKT dephosphorylating PIP3.45Vergadi Scholar,55Lu PTEN/PI3k/AKT regulates emphysematous mice.Scand. 85: 395-405Crossref (38) bladder regulated inhibiting PTEN enhanced STAT3 expression, promoting migration invasion.56Lin Yin H.B. X.Y. G.M. He W.Y. Gou Bladder cell-secreted activates progression.Int. 56: 151-164PubMed miR-130b-3p, miR-425-5p, miR-25-3p pathway. epithelial-mesenchymal transition (EMT) VEGF metastasis.57Wang Si Cui Qu contribute CXCL12/CXCR4-induced enhancing macrophages.Cancer 474: 36-52Crossref (108) Scholar,58Wang Corrigendum "Exosome-encapsulated macrophages" [Canc. 474 (2020) 36-52].Cancer 2022; 525: 200-202Crossref circFARSA upregulated non-small lung (NSCLC) exosomes.59Chen PTEN/PI3K/AKT metastasis.Cancer Treat. Commun. 100412Crossref (11) ubiquitination degradation PTEN, polarization.59Chen RNA-binding eIF4A3 triggered cyclization EMT NSCLC cells.59Chen STAT1/5 STAT 3/6 respectively.60Zhao Bian Y.Y. Y.J. Ma Y.T. Pei Zeng HuoXueTongFu formula alleviates intraperitoneal adhesion SOCS/JAK2/STAT/PPAR-γ signalling pathway.Mediators 2019: 1769374Crossref (14) Scholar,61Hu Ivashkiv L.B. Crosstalk among Jak-STAT, Toll-like receptor, ITAM-dependent activation.J. Leukoc. 2007; 82: 237-243Crossref (157) members suppressor (SOCS) family.60Zhao miR-29a-3p oral SOCS1/STAT6 signaling.62Cai Qiao Gao Oral carcinoma-derived subtype mediated exosome-enclosed miR-29a-3p.Am. 316: C731-C740Crossref co-culture system, miR-223 cervical (CSCC) CSCC creating positive feedback loop.63Zhang Qian STAT3-miR-223-TGFBR3/HMGCS1 axis modulates carcinoma.Mol. 14: 2313-2331Crossref Moreover, repressed TGFBR3 HMGCS1 UTRs, resulting anchorage-independent growth.63Zhang Hypoxia stimulates secretion, hypoxic trigger HIF1α- HIF2α-dependent manner.64Escribese Casas Corbí A.L. Influence oxygen tensions polarization.Immunobiology. 2012; 217: 1233-1240Crossref Scholar,65Díaz-Bulnes Saiz M.L. López-Larrea Rodríguez R.M. hypoxia ER stress res

Language: Английский

---

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Frontiers in Immunology, Journal Year: 2019, Volume and Issue: 10

Published: Nov. 14, 2019

Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults currently incurable. Despite multimodal treatment regimens, median survival unselected patient cohorts less than one year, recurrence remains almost inevitable. Escape from immune surveillance thought to contribute development progression of GB. While GB tumors are frequently infiltrated by natural killer (NK) cells, these actively suppressed cells microenvironment. Nevertheless, ex vivo activation with cytokines can restore cytolytic activity NK against GB, indicating that have potential for adoptive immunotherapy if potent cytotoxicity be maintained vivo. cancer not only their direct which triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also modulating T-cell mediated antitumor responses maintaining quality dendritic enhancing presentation antigens. Furthermore, similar T specific recognition elimination markedly enhanced expression chimeric antigen receptors (CARs), provides an opportunity generate NK-cell therapeutics defined specificity immunotherapy. Here we discuss effects microenvironment on functionality, summarize early attempts activated describe relevant CAR target antigens validated CAR-T cells. We then outline preclinical approaches employ CAR-NK immunotherapy, give overview ongoing clinical ErbB2 (HER2)-specific applied a phase I trial glioblastoma patients.

Language: Английский

---

The landscape of bispecific T cell engager in cancer treatment

Biomarker Research, Journal Year: 2021, Volume and Issue: 9(1)

Published: May 26, 2021

T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration the tumor site remain a major problem. To address this limitation, strategies for redirecting cells treat cancer are being intensively investigated, while bispecific cell engager (BiTE) therapy constitutes one most promising therapeutic approaches. BiTE is antibody construct with unique function, simultaneously binding an antigen on and surface molecule induce lysis. represented by blinatumomab has achieved impressive efficacy B malignancies. However, mechanisms resistance associated loss immunosuppressive factors such as upregulation immune checkpoints. Thus, modification constructs searching combination designed further enhance well reduce toxicity become urgent issue, especially solid tumors which always poor. In particular, focusing innate immunity attracted increasing interest shown anti-tumor activity engaging or innate-like cells, can be used alone complement current therapies. review, we depict landscape therapy, including clinical advances potential predictors, challenges resistance, developments novel therapy.

Language: Английский

---